• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Helo Corp Welcomes Kevin Fuller as President of Helo AI

    12/12/23 8:30:00 AM ET
    $NUS
    $USNA
    Other Pharmaceuticals
    Health Care
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $NUS alert in real time by email

    SAN FRANCISCO, CA / ACCESSWIRE / December 12, 2023 / Helo Corp. (OTC:HLOC) ("Helo" or the "Company") is pleased to announce that Kevin Fuller has joined its executive team as president of Helo AI and chief marketing officer of Helo, effective December 1, 2023.

    "We are delighted to welcome Kevin to our executive team," said Seán McVeigh, Helo's chief executive officer. "Kevin brings significant product development and marketing experience, arising from his previous roles as a senior executive with other leading technology and wellness companies. His passion and leadership add to the significant momentum of our Helo AI platform and upcoming products."

    Mr. Fuller, 53, served as cofounder and chief executive officer of MACUVU Macular Health from 2022 to 2023. From 2005 to 2021, he served as Senior Vice President of Global Product & Brand, and in other roles at Nu Skin (NYSE:NUS). From 1997 to 2005, Mr. Fuller served as Senior Product Manager at USANA (NYSE:USNA). Mr. Fuller received an M.B.A. degree from Brigham Young University and a B.S. in Biology from the University of Utah.

    "Helo is transforming the wellness technology category through integration of biodata, artificial intelligence and personalized nutrition," said Mr. Fuller. "The Company's history of innovation and focus on data-driven wellness are very compelling, but Helo's future wellness ecosystem will transcend current digital wellness solutions. I am excited to join the talented Helo team in building the future of wellness and nutrition powered by AI."

    About Helo Corp.

    Helo Corp. (OTC:HLOC)  is a data-driven wellness technology company. Helo wearables and other smart devices are built on Helo's Life Sensing Technology®, which uses state-of-the-art sensors, enhanced signal processing, and algorithms to collect and process specific bio-parameters. Helo is developing the Helo AI platform to leverage artificial intelligence and other technologies to analyze wearer data to provide recommendations that support the adoption of healthier lifestyle choices to drive human wellness transformation.

    For more information please visit helocorp.com.

    The Company's disclosure statements and financial statements are available at OTC PINK:HLOC.

    Forward Looking Statements

    This news release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," and similar statements. All statements other than statements of historical fact in this press release are forward-looking statements and involve certain risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. These forward-looking statements are based on management's current expectations, assumptions, estimates and projections about the Company and the industry in which the Company operates, but involve a number of unknown risks and uncertainties. Further information regarding these and other risks is included in the Company's filings with the OTC Markets and the Securities and Exchange Commission. The Company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and actual results may differ materially from the anticipated results. You are urged to consider these factors carefully in evaluating the forward-looking statements contained herein and are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by these cautionary statements.

    Investors Contact:
    [email protected]
    650-646-2193

    SOURCE: Helo Corp.



    View the original press release on accesswire.com

    Get the next $NUS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NUS
    $USNA

    CompanyDatePrice TargetRatingAnalyst
    USANA Health Sciences Inc.
    $USNA
    6/23/2023Buy
    Sidoti
    Nu Skin Enterprises Inc.
    $NUS
    1/31/2023$43.00 → $39.00Buy → Hold
    Jefferies
    USANA Health Sciences Inc.
    $USNA
    7/7/2022$78.00 → $53.00Hold → Underperform
    Jefferies
    USANA Health Sciences Inc.
    $USNA
    4/14/2022$86.00Neutral
    DA Davidson
    Nu Skin Enterprises Inc.
    $NUS
    2/17/2022$47.00 → $50.00Neutral
    DA Davidson
    Nu Skin Enterprises Inc.
    $NUS
    11/24/2021$43.00 → $49.00Neutral
    Citigroup
    Nu Skin Enterprises Inc.
    $NUS
    10/6/2021$61.00 → $47.00Neutral
    DA Davidson
    More analyst ratings

    $NUS
    $USNA
    Financials

    Live finance-specific insights

    See more
    • Nu Skin Enterprises Reports First Quarter Revenue at High End of Guidance

      Nu Skin Enterprises Inc. (NYSE:NUS) today announced first quarter revenue at the high end of its guidance range. Executive Summary Q1 2025 vs. Prior-year Quarter Revenue $364.5 million; (12.7)% (3.0)% FX impact or $(12.3) million Earnings Per Share (EPS) $2.14 or $0.23 excluding Mavely gain and other charges compared to $(0.01) or $0.09 excluding restructuring charges Customers 776,712; (11)% Paid Affiliates 131,518; (15)% Sales Leaders 31,036; (20)% "We are pleased to achieve revenue at the high end of our guidance range and exceed our adjusted earnings forecast to start out the year," said Ryan Napierski, Nu Skin president and CEO. "We drove

      5/8/25 4:06:00 PM ET
      $NUS
      Other Pharmaceuticals
      Health Care
    • Nu Skin Enterprises Announces Quarterly Dividend

      Nu Skin Enterprises, Inc. (NYSE:NUS) today announced its board of directors has declared a quarterly cash dividend of $0.06 per share, which will be paid on June 11, 2025, to shareholders of record on May 30, 2025. About Nu Skin Enterprises, Inc. The Nu Skin Enterprises Inc. (NYSE:NUS) family of companies includes Nu Skin and Rhyz Inc. Nu Skin is an integrated beauty and wellness company, powered by a dynamic affiliate opportunity platform, which operates in nearly 50 markets worldwide. Backed by 40 years of scientific research, the company's products help people look, feel and live their best with brands including Nu Skin® personal care, Pharmanex® nutrition and ageLOC® anti-aging, which

      5/8/25 4:05:00 PM ET
      $NUS
      Other Pharmaceuticals
      Health Care
    • USANA Health Sciences Reports First Quarter 2025 Results and Reiterates Full-Year Outlook

      USANA Health Sciences, Inc. (NYSE:USNA) today announced financial results for its fiscal first quarter ended March 29, 2025. Key Financial Results First Quarter 2025 vs. First Quarter 2024 Net sales of $250 million versus $228 million, representing year-over-year growth of 10% and 12% in constant currency. Net earnings of $9.4 million versus $16.5 million. Diluted EPS of $0.49 as compared with $0.86. Adjusted diluted EPS(1) of $0.73 as compared with $0.86. Adjusted EBITDA(2) of $30 million versus $33 million. Direct selling Active Customers of 459,000 versus 494,000. Hiya Active Monthly Subscribers of 224,000. Company reiterates fiscal year 2025 outlook. Q1 2025 Financia

      4/22/25 4:05:00 PM ET
      $USNA
      Medicinal Chemicals and Botanical Products
      Health Care

    $NUS
    $USNA
    SEC Filings

    See more
    • SEC Form 10-Q filed by Nu Skin Enterprises Inc.

      10-Q - NU SKIN ENTERPRISES, INC. (0001021561) (Filer)

      5/8/25 8:52:03 PM ET
      $NUS
      Other Pharmaceuticals
      Health Care
    • Nu Skin Enterprises Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - NU SKIN ENTERPRISES, INC. (0001021561) (Filer)

      5/8/25 4:16:05 PM ET
      $NUS
      Other Pharmaceuticals
      Health Care
    • SEC Form 10-Q filed by USANA Health Sciences Inc.

      10-Q - USANA HEALTH SCIENCES INC (0000896264) (Filer)

      5/6/25 2:42:26 PM ET
      $USNA
      Medicinal Chemicals and Botanical Products
      Health Care

    $NUS
    $USNA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Nu Skin Enterprises Reports First Quarter Revenue at High End of Guidance

      Nu Skin Enterprises Inc. (NYSE:NUS) today announced first quarter revenue at the high end of its guidance range. Executive Summary Q1 2025 vs. Prior-year Quarter Revenue $364.5 million; (12.7)% (3.0)% FX impact or $(12.3) million Earnings Per Share (EPS) $2.14 or $0.23 excluding Mavely gain and other charges compared to $(0.01) or $0.09 excluding restructuring charges Customers 776,712; (11)% Paid Affiliates 131,518; (15)% Sales Leaders 31,036; (20)% "We are pleased to achieve revenue at the high end of our guidance range and exceed our adjusted earnings forecast to start out the year," said Ryan Napierski, Nu Skin president and CEO. "We drove

      5/8/25 4:06:00 PM ET
      $NUS
      Other Pharmaceuticals
      Health Care
    • Nu Skin Enterprises Announces Quarterly Dividend

      Nu Skin Enterprises, Inc. (NYSE:NUS) today announced its board of directors has declared a quarterly cash dividend of $0.06 per share, which will be paid on June 11, 2025, to shareholders of record on May 30, 2025. About Nu Skin Enterprises, Inc. The Nu Skin Enterprises Inc. (NYSE:NUS) family of companies includes Nu Skin and Rhyz Inc. Nu Skin is an integrated beauty and wellness company, powered by a dynamic affiliate opportunity platform, which operates in nearly 50 markets worldwide. Backed by 40 years of scientific research, the company's products help people look, feel and live their best with brands including Nu Skin® personal care, Pharmanex® nutrition and ageLOC® anti-aging, which

      5/8/25 4:05:00 PM ET
      $NUS
      Other Pharmaceuticals
      Health Care
    • USANA Releases 2024 Sustainability Report

      Highlighting USANA's ongoing commitment to people, planet, and products SALT LAKE CITY, May 8, 2025 /PRNewswire/ -- As a global leader in health and wellness, USANA is dedicated to doing its part in creating a better, healthier world. And with a commitment to positive business practices, USANA recently released its fifth annual sustainability report. This review of USANA's 2024 sustainability efforts and progress includes organizational priorities based on a comprehensive stakeholder assessment. To view the full 2024 sustainability report, please click here. "In unveiling our

      5/8/25 8:56:00 AM ET
      $USNA
      Medicinal Chemicals and Botanical Products
      Health Care

    $NUS
    $USNA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Nu Skin Enterprises Inc.

      SC 13G/A - NU SKIN ENTERPRISES, INC. (0001021561) (Subject)

      11/12/24 4:47:17 PM ET
      $NUS
      Other Pharmaceuticals
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Nu Skin Enterprises Inc.

      SC 13G/A - NU SKIN ENTERPRISES, INC. (0001021561) (Subject)

      11/6/24 10:20:59 AM ET
      $NUS
      Other Pharmaceuticals
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Nu Skin Enterprises Inc.

      SC 13G/A - NU SKIN ENTERPRISES, INC. (0001021561) (Subject)

      11/4/24 10:21:31 AM ET
      $NUS
      Other Pharmaceuticals
      Health Care

    $NUS
    $USNA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Sidoti initiated coverage on USANA

      Sidoti initiated coverage of USANA with a rating of Buy

      6/23/23 9:12:38 AM ET
      $USNA
      Medicinal Chemicals and Botanical Products
      Health Care
    • Nu Skin downgraded by Jefferies with a new price target

      Jefferies downgraded Nu Skin from Buy to Hold and set a new price target of $39.00 from $43.00 previously

      1/31/23 6:17:27 AM ET
      $NUS
      Other Pharmaceuticals
      Health Care
    • USANA downgraded by Jefferies with a new price target

      Jefferies downgraded USANA from Hold to Underperform and set a new price target of $53.00 from $78.00 previously

      7/7/22 9:35:48 AM ET
      $USNA
      Medicinal Chemicals and Botanical Products
      Health Care

    $NUS
    $USNA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CHIEF FINANCIAL OFFICER Iiekking G Doug sold $134,662 worth of shares (4,548 units at $29.61), closing all direct ownership in the company (SEC Form 4)

      4 - USANA HEALTH SCIENCES INC (0000896264) (Issuer)

      5/12/25 10:42:33 AM ET
      $USNA
      Medicinal Chemicals and Botanical Products
      Health Care
    • Director Wood Timothy E converted options into 674 shares and covered exercise/tax liability with 169 shares, increasing direct ownership by 7% to 7,442 units (SEC Form 4)

      4 - USANA HEALTH SCIENCES INC (0000896264) (Issuer)

      5/6/25 4:02:48 PM ET
      $USNA
      Medicinal Chemicals and Botanical Products
      Health Care
    • Director Winssinger Frederic J converted options into 674 shares, increasing direct ownership by 13% to 5,871 units (SEC Form 4)

      4 - USANA HEALTH SCIENCES INC (0000896264) (Issuer)

      5/6/25 4:01:06 PM ET
      $USNA
      Medicinal Chemicals and Botanical Products
      Health Care

    $NUS
    $USNA
    Leadership Updates

    Live Leadership Updates

    See more
    • USANA Exec. Chairman Kevin Guest Celebrates Guitar Month, Stress Awareness Month for Harmony

      SALT LAKE CITY, April 1, 2025 /PRNewswire/ -- USANA Health Sciences (NYSE:USNA) Executive Chairman Kevin Guest marks April's convergence of International Guitar Month and Stress Awareness Month, as a perfect pairing that celebrates the healing power of music for mental well-being. While music has long been heralded as a universal remedy, the guitar offers far more than just melodies. Studies, stories and specialists alike agree: playing the guitar is a proven method to reduce stress. A passionate, performing guitarist himself, Guest invites others to join the cause. "Music has

      4/1/25 7:47:00 AM ET
      $USNA
      Medicinal Chemicals and Botanical Products
      Health Care
    • USANA Appoints New Chief Scientific Officer

      Dr. Kathryn Armstrong brings 17 years of scientific expertise to the company SALT LAKE CITY, Jan. 22, 2025 /PRNewswire/ -- USANA Health Sciences, Inc., a global leader in cellular nutrition, is proud to announce that Dr. Kathryn Armstrong, Ph.D., will be assuming the role of chief scientific officer at the company. Kathryn has served as USANA's executive vice president of research and development since July of 2024.  Kathryn's predecessor, Dr. Rob Sinnott, announced his retirement at the end of 2024, but will continue to assist in the company's pursuit for scientific excellence as its senior scientific fellow.

      1/22/25 7:07:00 AM ET
      $USNA
      Medicinal Chemicals and Botanical Products
      Health Care
    • Nu Skin Enterprises Appoints Mark A. Zorko to Board of Directors

      Nu Skin Enterprises (NYSE:NUS) today announced the appointment of Mark A. Zorko, a principal with executive management association Brentwood Advisory Group, to the company's board of directors. The board also appointed Zorko to serve on its audit committee and the nominating and corporate governance committee. "Mark brings extensive C-level leadership experience with several global public companies, as well as more than 20 years of board-level experience," said Steven J. Lund, executive chairman of the board. "We welcome Mark to the board and look forward to leveraging his extensive business insights and experience." Zorko is a principal with Brentwood Advisory, an association he co-found

      9/12/24 4:05:00 PM ET
      $NUS
      Other Pharmaceuticals
      Health Care